HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis.
BACKGROUND
We performed a pooled analysis of randomised clinical trials (RCT) on HPV vaccine efficacy in preventing cervical persistent infection.


METHODS
We carried out a bibliographic search on electronic databases and we selected RCT to perform the meta-analyses.


RESULTS
We selected five studies. The first meta-analysis, including all studies, showed an important reduction of the risk of infection from HPV 16 in vaccinated cohort [RR 0.10 (95% CI: 0.07-0.15)]. The second and third meta-analyses, including only studies on bivalent and tetravalent vaccines, showed a RR of 0.13 (95% CI: 0.09-0.20) for HPV 16 infections and a RR of 0.22 (95% CI: 0.13-0.38) for HPV 18 ones.


CONCLUSIONS
HPV vaccine efficacy in preventing persistent infection is high but there is the need for further studies on the duration of immunization and long-term vaccine efficacy.
La Torre
G
G
Institute of Hygiene, Catholic University of the Sacred Heart-Rome, Largo F. Vito 1, 00168 Rome, Italy. giuseppe.latorre@rm.unicatt.it
de Waure
C
C
Chiaradia
G
G
Mannocci
A
A
Ricciardi
W
W
D000293:Adolescent; D000328:Adult; D005260:Female; D052162:Human papillomavirus 16; D052161:Human papillomavirus 18; D006801:Humans; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000517:prevention & control / Q000821:virology
D053918:Papillomavirus Vaccines